89bio, Inc. Common Stock
Symbol: ETNB (NASDAQ)
Company Description:
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
- Today's Open: $14.79
- Today's High: $14.845
- Today's Low: $14.79
- Today's Volume: 1.14M
- Yesterday Close: $14.8
- Yesterday High: $14.83
- Yesterday Low: $14.77
- Yesterday Volume: 2.97M
- Last Min Volume: 143
- Last Min High: $14.795
- Last Min Low: $14.795
- Last Min VWAP: $14.795
- Name: 89bio, Inc. Common Stock
- Website: https://www.89bio.com
- Listed Date: 2019-11-11
- Location: SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001785173
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $2.20B
- Round Lot: 100
- Outstanding Shares: 148.49M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-10-07 | SCHEDULE 13G/A | View |
2025-10-03 | SCHEDULE 13D | View |
2025-10-01 | SC 14D9 | View |
2025-10-01 | SC TO-T | View |
2025-09-24 | SC14D9C | View |
2025-09-19 | SC14D9C | View |
2025-09-18 | SC TO-C | View |
2025-09-18 | SC TO-C | View |
2025-09-18 | SC14D9C | View |
2025-09-18 | 8-K | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-08 | 10-Q | View |
2025-08-07 | 8-K | View |
2025-08-05 | 4 | View |
2025-08-05 | 4 | View |
2025-08-05 | 4 | View |
2025-08-05 | 4 | View |
2025-08-05 | 4 | View |
2025-07-29 | SCHEDULE 13G | View |
2025-07-17 | 4 | View |